


# Docking of small molecules. Vina.



**Marc A. Marti-Renom**

<http://bioinfo.cipf.es/squ/>

Structural Genomics Unit  
Bioinformatics Department

Prince Felipe Research Center (CIPF), Valencia, Spain



**PRINCIPE FELIPE**  
CENTRO DE INVESTIGACION

# Objective

TO LEARN **HOW-TO** USE AutoDock  
VINA FOR DOCKING SMALL  
MOLECULES IN THE SURFACE OF A  
PROTEIN

# Nomenclature

**Ligand:** Structure (usually a small molecule) that binds to the binding site.

**Receptor:** Structure (usually a protein) that contains the active binding site.

**Binding site:** Set of aminoacids (residues) that physically interact with the ligand (usually within 6 Ångstroms).

# DISCLAIMER!

*Credit should go to Dr. Oleg Trott, Dr. Ruth Huey and Dr. Garret M. Morris*

## Using AutoDock 4 with ADT: A Tutorial

*Dr. Ruth Huey  
&  
Dr. Garrett M. Morris*

<http://autodock.scripps.edu>

<http://vina.scripps.edu>

### Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading

OLEG TROTT, ARTHUR J. OLSON  
Department of Molecular Biology, The Scripps Research Institute, La Jolla, California

Received 3 March 2009; Accepted 21 April 2009

DOI 10.1002/jcc.21334  
Published online in Wiley InterScience (www.interscience.wiley.com).

**Abstract:** AutoDock Vina, a new program for molecular docking and virtual screening, is presented. AutoDock Vina achieves an approximately two orders of magnitude speed-up compared with the molecular docking software previously developed in our lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by our tests on the training set used in AutoDock 4 development. Further speed-up is achieved from parallelism, by using multithreading on multicore machines. AutoDock Vina automatically calculates the grid maps and clusters the results in a way transparent to the user.

© 2009 Wiley Periodicals, Inc. J Comput Chem 00: 000–000, 2009

**Key words:** AutoDock; molecular docking; virtual screening; computer-aided drug design; multithreading; scoring function

#### Introduction

Molecular docking is a computational procedure that attempts to predict noncovalent binding of macromolecules or, more frequently, of a macromolecule (receptor) and a small molecule (ligand) efficiently, starting with their unbound structures, structures obtained from MD simulations, or homology modeling, etc. The goal is to predict the bound conformations and the binding affinity.

The prediction of binding of small molecules to proteins is of particular practical importance because it is used to screen virtual libraries of drug-like molecules to obtain leads for further drug development. Docking can also be used to try to predict the bound conformation of known binders, when the experimental holo structures are unavailable.<sup>1</sup>

One is interested in maximizing the accuracy of these predictions while minimizing the computer time they take, because the computational resources spent on docking are considerable. For example, hundreds of thousands of computers are used for running docking in P1ghtAIDS@Home and similar projects.<sup>2</sup>

#### Theory

In the spectrum of computational approaches to modeling receptor–ligand binding,

- molecular dynamics with explicit solvent,
- molecular dynamics and molecular mechanics with implicit solvent, and
- molecular docking

can be seen as making an increasing trade-off of the representational detail for computational speed.<sup>3</sup>

Among the assumptions made by these approaches is the commitment to a particular protonation state of and charge distribution in the molecules that do not change between, for example, their bound and unbound states. Additionally, docking generally assumes much or all of the receptor rigid, the covalent lengths, and angles constant, while considering a chosen set of covalent bonds freely rotatable (referred to as active rotatable bonds here).

Importantly, although molecular dynamics directly deals with energies (referred to as force fields in chemistry), docking is ultimately interested in reproducing chemical potentials, which determine the bound conformation preference and the free energy of binding. It is a qualitatively different concept governed not only by the minima in the energy profile but also by the shape of the profile and the temperature.<sup>4,5</sup>

Docking programs generally use a scoring function, which can be seen as an attempt to approximate the standard chemical potentials of the system. When the superficially physics-based terms like the 6–12 van der Waals interactions and Coulomb energies are used in the scoring function, they need to be significantly empirically weighted, in part, to account for this difference between energies and free energies.<sup>4,5</sup>

**Correspondence to:** A.J. Olson; e-mail: olson@scripps.edu  
Contract/grant sponsor: NIH; contract/grant number: 2R01GM069832

© 2009 Wiley Periodicals, Inc.

O. Trott, A. J. Olson, *Journal of Computational Chemistry* (2009)


# Summary

- **INTRO**
  - **DOCKING**
  - **SEARCH METHODS**
  - **EXAMPLE**
- 
- **Vina 1.1.1 with ADT**

# What is docking?

**Predicting the best ways two molecules interact.**

- ◆ Obtain the 3D structures of the two molecules
- ◆ Locate the best binding site (**Remember AnnoLyze? :-)**)
- ◆ Determine the best binding mode.






# What is docking?

Predicting the **best** ways two molecules interact.


- ◆ We need to quantify or rank solutions
- ◆ We need a good scoring function for such ranking



# What is docking?

Predicting the best **ways** two molecules interact.


- ◆ X-ray and NMR structures are just ONE of the possible solutions
- ◆ There is a need for a search solution



Sampling!



# REPRESENTATION




# SCORING



## AutoDock Vina

$$\Delta G_{binding} = \Delta G_{vdW} + \Delta G_{elec} + \Delta G_{hbond} + \Delta G_{desolv} + \Delta G_{tors}$$

- $\Delta G_{vdW}$   
12-6 Lennard-Jones potential
- $\Delta G_{elec}$   
Coulombic with Solmajer-dielectric
- $\Delta G_{hbond}$   
12-10 Potential with Goodford Directionality
- $\Delta G_{desolv}$   
Stouten Pairwise Atomic Solvation Parameters
- $\Delta G_{tors}$   
Number of rotatable bonds




$$\epsilon(r) = A + \frac{B}{1 + ke^{-\lambda Br}}$$



# PROBLEM!

Very CPU time consuming...



Dihydrofolate reductase with a metotrexate (4dfr.pdb)

$$N = T^{360/i}$$

*N*: number of conformations

*T*: number of rotatable bonds

*i*: incremental degrees

**Metotrexato**


10 rotatable bonds

30° increments (discrete)

**$10^{12}$  plausible conformations!**

# SOLUTION

## Use of grid maps!




- ◆ Saves lots of time (compared to classical MM/MD)
- ◆ Need to map each atom to a grid point
- ◆ Limits the search space!

# AutoGrid Vina

## Use of grid maps!


- ◆ Center of grid \*
  - ◆ center of ligand
  - ◆ center of receptor
  - ◆ a selected atom or coordinate
- ◆ Box dimension \*
- ◆ Grid resolution (spacing)
  - ◆ default 0.375 Angstroms
- ◆ Number of grid points (dimension)
  - ◆ use ONLY even numbers
- ◆ MAKE SURE ALL LIGAND IS INSIDE GRID AND CAN MOVE!



With VINA much simplified (\*)

# Search algorithms

## Simulated Annealing





# Search algorithms

## Genetic Algorithm


### Use of a Genetic Algorithm as a sampling method

- Each conformation is described as a set of rotational angles.
- 64 possible angles are allowed to each of the bond in the ligand.
- Each plausible dihedral angle is codified in a set of binary bits ( $2^6=64$ )
- Each conformation is codified by a so called chromosome with  $4 \times 6$  bits (0 or 1)

**111010.010110.001011.010010**

$\underbrace{\hspace{1.5cm}}_{\Phi_1} \underbrace{\hspace{1.5cm}}_{\Phi_2} \dots$




$$\Phi_1 = 1 \times 2^5 + 1 \times 2^4 + 1 \times 2^3 + 0 \times 2^2 + 1 \times 2^1 + 0 \times 2^0 = 58^\circ$$



# Search algorithms

## Genetic Algorithm

Population (*ie*, set of chromosomes or configurations)



011010.010110.011010.010111  
111010.010110.001011.010010  
001010.010101.000101.010001  
101001.101110.101010.001000  
001010.101000.011101.001011



← Chromosome

Gene

# Search algorithms

## Genetic Algorithm

### Genetic operators...



011010.010110.011010.010111





Single  
mutation

011010.01**1**110.011**1**10.010111

# Search algorithms

## Genetic Algorithm

### Genetic operators...



001010.010101.000101.010001

011010.010110.011010.010111

Recombination

001010.010101.011010.010111

011010.010110. 000101.010001

# Search algorithms

## Genetic Algorithm

### Genetic operators...

011010.010110.011010.010111  
111010.010110.001011.010010  
001010.010101.000101.010001  
101001.101110.101010.001000  
001010.101000.011101.001011

Migration




111110.010010.011110.010101  
101010.110110.011011.011010  
001010.010101.000101.010001  
101101.101010.101011.001100  
011010.100000.011001.101011

# AutoDock Example

## Discovery of a novel binding trench in HIV Integrase

Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. J Med Chem, 2004. 47(8): 1879-81

Where patients come first  MERCK

Patients & Caregivers | Healthcare Professionals | Worldwide

Quick Find  Search

[HOME](#) | [ABOUT MERCK](#) | [PRODUCTS](#) | [NEWSROOM](#) | [INVESTOR RELATIONS](#) | [CAREERS](#) | [RESEARCH](#) | [LICENSING](#) | [THE MERCK MANUALS](#)

Newsroom

[Product News](#)

[Research & Development News](#)

[Corporate News](#)

[Financial News](#)

[Corporate Responsibility News](#)

[Fact Sheet](#)

[Executive Speeches](#)

[Webcasts](#)


[VIOXX® \(rofecoxib\) Information Center](#)

[Contact Newsroom](#)

[Podcast](#)

[RSS](#)

Product News



### FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor

WHITEHOUSE STATION, N.J., Oct. 12, 2007 - Merck & Co., Inc., announced today that the U.S. Food and Drug Administration (FDA) granted ISENTRESS™ (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS [pronounced i-sen-tris]. These studies were conducted in clinically advanced, three-class antiretroviral [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] treatment-experienced adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.

ISENTRESS® data will be required before the FDA can consider traditional approval for effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term patients or pediatric patients. There are no study results demonstrating the efficacy of ISENTRESS have not been established in treatment-naïve adult associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.


ABOUT ISENTRESS

[Full Prescribing Information](#)

[Patient Product Information](#)




# ISENTRESS example






- One structure known with 5CITEP
  - Not clear (low resolution)
  - Binding near to DNA interacting site
  - Loop near the binding
- Docking + Molecular Dynamics
  - AMBER snapshots
  - AutoDock flexible torsion thetetrazolering and indole ring.

# ISENTRESS example






Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. *J Med Chem*, 2004. 47(8): 1879-81

# ISENTRESS example




# ISENTRESS example



Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. J Med Chem, 2004. 47(8): 1879-81

# ISENTRESS example

Where patients come first  **MERCK**

Patients & Caregivers | Healthcare Professionals | Worldwide

Quick Find  Search

[HOME](#) | [ABOUT MERCK](#) | [PRODUCTS](#) | [NEWSROOM](#) | [INVESTOR RELATIONS](#) | [CAREERS](#) | [RESEARCH](#) | [LICENSING](#) | [THE MERCK MANUALS](#)

**Newsroom**

[Product News](#)

[Research & Development News](#)

[Corporate News](#)

[Financial News](#)

[Corporate Responsibility News](#)

[Fact Sheet](#)

[Executive Speeches](#)

[Webcasts](#)


[VIOXX® \(rofecoxib\) Information Center](#)

[Contact Newsroom](#)

[Podcast](#)

[RSS](#)

**Product News**



## FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor

WHITEHOUSE STATION, N.J., Oct. 12, 2007 - Merck & Co., Inc., announced today that the U.S. Food and Drug Administration (FDA) granted ISENTRESS™ (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS [pronounced i-sen-tris]. These studies were conducted in clinically advanced, three-class antiretroviral [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] treatment-experienced adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.

**ABOUT ISENTRESS**

[Full Prescribing Information](#)

[Patient Product Information](#)

ISENTRESS™  
data will be required before the FDA can consider traditional approval for  
effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term  
benefits or harms have not been established. There are no study results demonstrating the








# Vina 1.1.1

Goodsell, D. S. and Olson, A. J. (1990), Automated Docking of Substrates to Proteins by Simulated Annealing Proteins:Structure, Function and Genetics., 8: 195-202.  
Morris, G. M., et al. (1996), Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 J. Computer-Aided Molecular Design, 10: 293-304.  
Morris, G. M., et al. (1998), Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function J. Computational Chemistry, 19: 1639-1662.  
Huey, R., et al. (2007), A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Computational Chemistry, 28: 1145-1152.


# Vina 1.1.1



Goodsell, D. S. and Olson, A. J. (1990), Automated Docking of Substrates to Proteins by Simulated Annealing Proteins:Structure, Function and Genetics., 8: 195-202.  
Morris, G. M., et al. (1996), Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 J. Computer-Aided Molecular Design, 10: 293-304.  
Morris, G. M., et al. (1998), Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function J. Computational Chemistry, 19: 1639-1662.  
Huey, R., et al. (2007), A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Computational Chemistry, 28: 1145-1152.

# Vina 1.1.1

## Where to get help...



The screenshot shows a web browser window with the title "AutoDock Vina - molecular docking and virtual screening program". The address bar shows the URL "http://vina.scripps.edu/". The website has a navigation bar with links: Home, Download, Tutorial, Manual, and Forum. The main content area features four molecular docking visualizations labeled (a), (b), (c), and (d). Each image shows a green molecular structure docked into a yellow and blue surface representation of a protein binding site. The text on the page describes AutoDock Vina as a new program for drug discovery, molecular docking, and virtual screening, designed and implemented by Dr. Oleg Trost. It also mentions that the images illustrate flexible docking results superimposed on crystal structures of various drugs.

AutoDock Vina – molecular docking and virtual screening program

http://vina.scripps.edu/

Home Download Tutorial Manual Forum

### AutoDock Vina

AutoDock Vina is a new program for drug discovery, [molecular docking](#) and virtual screening, offering multi-core capability, high performance and enhanced accuracy and ease of use. [\[1\]](#)


AutoDock Vina has been designed and implemented by [Dr. Oleg Trost](#) in the Molecular Graphics Lab at The Scripps Research Institute.

The image on the left illustrates the results of flexible docking (green) superimposed on the crystal structures of (a) indinavir, (b) atorvastatin, (c) imatinib, and (d) oseltamivir.

<http://vina.scripps.edu>


# Vina 1.1.1

## Alternatives



# AutoDock 4.0


## Why AutoDock over others





# AutoDock 4.0

## Why AutoDock over others




Sousa, S.F., Fernandes, P.A. & Ramos, M.J. (2006)  
**Protein-Ligand Docking: Current Status  
and Future Challenges** *Proteins*, **65**:15-26



# AutoDock 4.0

## Why AutoDock over others

Most Common Docking Programs



# AutoDock / Vina

## Practical considerations

- \* What problem does AutoDock solve?
  - \* *Flexible* ligands (4.0 *flexible* protein).
- \* What range of problems is feasible?
  - \* Depends on the search method:
    - \* **LGA** > **GA** >> **SA** >> **LS**
    - \* **SA** : can output trajectories,  $D < \text{about } 8 \text{ torsions}$ .
    - \* **LGA** :  $D < \text{about } 8\text{-}32 \text{ torsions}$ .
- \* When is AutoDock not suitable?
  - \* No 3D-structures are available;
  - \* Modelled structure of poor quality;
  - \* Too many (32 torsions, 2048 atoms, 22 atom types);
  - \* Target protein too flexible.

# Vina 1.1.1

## Things to know before using AutoDock

### *Ligand:*


- \* Add all hydrogens, compute Gasteiger charges, and merge non-polar H; also assign AutoDock 4 atom types
- \* Ensure total charge corresponds to tautomeric state
- \* Choose torsion tree root & rotatable bonds

### *Macromolecule:*

- \* Add all hydrogens, compute Gasteiger charges, and merge non-polar H; also assign AutoDock 4 atom types
- \* Assign Stouten atomic solvation parameters
- \* Optionally, create a flexible residues PDBQT in addition to the rigid PDBQT file
- \* Compute AutoGrid maps

# Vina 1.1.1

Good that we have AutoDock Tools (ATD)




<http://autodock.scripps.edu/resources/adt>



# Vina 1.1.1

Good we have a nice tutorial



<http://vina.scripps.edu/>

# Acknowledgements

This presentation was based on:

**“Using AutoDock 4 with ADT. A tutorial”**  
by Dr. Ruth Huey and Dr. Garret M. Morris

**Vina Tutorial**  
by Dr. Oleg Trott

